Patrick Honoré
Corporate Officer/Principal bij AM-Pharma Holding BV
Oorsprong van het eerstegraads netwerk van Patrick Honoré
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.
12
| Subsidiary | Pharmaceuticals: Major | 12 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.
12
| Holding Company | Biotechnology | 12 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Patrick Honoré via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| The American University of Rome | College/University | Doctorate Degree | |
| TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member | |
Biotie Therapies AG
 Biotie Therapies AG Pharmaceuticals: MajorHealth Technology Part of Acorda Therapeutics, Inc., Biotie Therapies AG is a holding Swiss company focused on developing drugs for the treatment of psychiatry and neurology diseases. The company is based in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
| BIOTIE THERAPIES CORP | Pharmaceuticals: Major | Director/Board Member | |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Founder Private Equity Analyst | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Middlebury College | College/University | Undergraduate Degree | |
| University of Amsterdam | College/University | Undergraduate Degree Graduate Degree | |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| University of Utrecht | College/University | Doctorate Degree Graduate Degree | |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Investment Managers | Private Equity Investor | |
Otsuka America Pharmaceutical, Inc.
 Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | Pharmaceuticals: Major | Chief Executive Officer | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Chairman Director/Board Member Director/Board Member | |
Kurma Partners SA
 Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Versant EuroVentures | Chief Executive Officer | ||
Anabasis SRL
 Anabasis SRL Miscellaneous Commercial ServicesCommercial Services Part of Dompé SpA, Anabasis SRL provides biopharmaceutical research and development services. The company is based in Milan, Italy. The Italian company was founded by Francesco Sinigaglia. Anabasis was acquired by Dompé SpA on February 27, 2012. | Miscellaneous Commercial Services | Director/Board Member | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member | |
| AXONICS, INC. | Medical Specialties | Chairman | |
PIQUR Therapeutics AG
 PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Other | Director/Board Member | |
| Axonics Europe SAS | Chief Executive Officer | ||
Mosaic Biomedicals SL
 Mosaic Biomedicals SL Hospital/Nursing ManagementHealth Services Mosaic Biomedicals SL develops personalized cancer treatments. It is engaged in the realization and development of scientific and technical research projects in the field of oncological and tumor diseases. The company was founded by Joan Seoane, Judit Anido Folgueira and José Baselga on April 19, 2013 and is headquartered in Barcelona, Spain. | Hospital/Nursing Management | Director/Board Member | |
SoniVie Ltd.
 SoniVie Ltd. Medical SpecialtiesHealth Technology SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel. | Medical Specialties | Director/Board Member | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Chairman | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| MYOVANT SCIENCES LTD. | Biotechnology | Director/Board Member | |
| Versant Ventures (Switzerland) GmbH | Investment Managers | Private Equity Investor | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member Founder Director/Board Member | |
Arvelle Therapeutics International GmbH
 Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Founder | |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| APREA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Nouscom Srl | Miscellaneous Commercial Services | Director/Board Member | |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Winch Italy Holding 2 SARL | Director/Board Member |
Statistieken
Internationaal
| Zwitserland | 11 |
| Nederland | 10 |
| Frankrijk | 10 |
| Verenigde Staten | 9 |
| Italië | 4 |
Sectoraal
| Health Technology | 33 |
| Finance | 6 |
| Consumer Services | 5 |
| Commercial Services | 5 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 185 |
| Corporate Officer/Principal | 50 |
| Chairman | 34 |
| Independent Dir/Board Member | 23 |
| Private Equity Investor | 18 |
Sterkste connecties
| Insiders | |
|---|---|
| Raphaël Wisniewski | 45 |
| Martijn Kleijwegt | 33 |
| Russell Greig | 31 |
| Rémi Droller | 29 |
| Guido Magni | 23 |
| Ashok Dhanrajgir | 21 |
| Geert-Jan Mulder | 17 |
| Joël Jean-Mairet | 17 |
| Klaus Breiner | 16 |
| Mark Altmeyer | 16 |
| Andrea van Elsas | 16 |
| Edwin de Graaf | 14 |
| Rita Jain | 14 |
| Erik van den Berg | 13 |
| Felice Verduyn-van Weegen | 9 |
- Beurs
- Insiders
- Patrick Honoré
- Bedrijfsconnecties
